Drug intelligence / Profile preview

INT-787

Development stage: Discontinued
Lead developer: Alfasigma
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

INT-787 is a hydrophilic, semisynthetic bile acid–derived small molecule that acts as a selective next-generation agonist of the farnesoid X receptor (FXR). It is being developed by Intercept Pharmaceuticals for the treatment of severe alcohol-associated hepatitis (sAH), a life-threatening liver condition with limited treatment options. INT-787 has demonstrated greater efficacy than obeticholic acid (OCA) in preclinical models, showing significant reductions in liver inflammation, fibrosis markers, and improvement in gut barrier function. The drug is currently undergoing Phase 2a clinical trials to assess its safety, tolerability, pharmacokinetics, and efficacy in patients with sAH.

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on INT-787.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-787.

Explore the full profile